Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Patient characteristics and treatment outcomes with Pola-R-CHP: A real-world study of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in the United States (US)

Patrick Reagan, Natasha Shamas, Anthony Masaquel et al. Nov 03, 2025 pp. 6265-6265 10.1182/blood-2025-6265

Abstract Background: The Phase III POLARIX study reported improved progression-free survival (PFS) of polatuzumab vedotin (Pola) in combinat...

A ubiquitin specific protease (USP) network regulates wnt/β-catenin activity in myeloid leukemia cells

Megan Wagstaff, Okan Sevim, Maddie Harrison et al. Nov 03, 2025 pp. 6770-6770 10.1182/blood-2025-6770

Abstract Canonical Wnt signalling is an important regulator of haematopoietic stem/progenitor cells (HSPC) and frequently dysregulated in my...

Prognostic impact of donor KIR genotypes on clinical outcomes in pediatric allogeneic hematopoietic stem cell transplantation

Uet Yu, Qi Luo, Xiaodong Wang et al. Nov 03, 2025 pp. 172-172 10.1182/blood-2025-172

Abstract Prognostic Impact of Donor KIR Genotypes on Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Backg...

Real-world data of adolescents and young adults with acute lymphoblastic leukemia treated with a modified GMALL protocol in India: Treatment outcomes and challenges

Uday Kulkarni, Sushil Selvarajan, Anu Korula et al. Nov 03, 2025 pp. 6321-6321 10.1182/blood-2025-6321

Abstract Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated using pediatric-inspired regimens have improved...

Coexisting trisomies of chromosomes 12 and 19 define a cytogenetic subgroup of IgG+ CLL enriched for BIRC3 mutations

Marina Gerousi, Antonia-Zoe Kouroutzidou, Anastasia Iatrou et al. Nov 03, 2025 pp. 7410-7410 10.1182/blood-2025-7410

Abstract Introduction: Coexisting trisomies of chromosomes 12 and 19 define a cytogenetic subgroup of CLL (+12+19 CLL) with shared clinicobi...

Momelotinib's unique polypharmacology supports indication expansion beyond myelofibrosis

Shane O'Brien, Henrik Hammarén, Bryan Strouse et al. Nov 03, 2025 pp. 7853-7853 10.1182/blood-2025-7853

Abstract Momelotinib (Ojjaara / Omjjara), a clinically differentiated JAK inhibitor, not only addresses symptoms and splenomegaly associated...

Prevalence of iron deficiency among youth with sickle cell disease

Anyssa Young, Brett Klamer, Amanda Jacobson-Kelly et al. Nov 03, 2025 pp. 6467-6467 10.1182/blood-2025-6467

Abstract Sickle cell disease (SCD) is an inherited hemoglobinopathy affecting up to 100,000 people in the United States. While pain, acute c...

Impact of infectious complications on outcomes after allogeneic hematopoietic stem cell transplantation in elderly patients: A geth-TC study

Sara Fernandez-Luis, Mónica Baile González, Alejandro Avendaño et al. Nov 03, 2025 pp. 6039-6039 10.1182/blood-2025-6039

Abstract Introduction Allogeneic hematopoietic stem cell transplantation (alloHSCT) is increasingly performed in elderly patients, a populat...

Benefits of hydroxyurea in hemoglobin SC: Results of the open-label phase of the prospective identification of variables as outcomes for treatment (PIVOT) trial

Luke Smart, Yvonne Dei-Adomakoh, Adam Lane et al. Nov 03, 2025 pp. 409-409 10.1182/blood-2025-409

Abstract Introduction: Hydroxyurea treatment is the standard of care for people with sickle cell anemia (HbSS or HbS/beta-zero thalassemia)...

Closing the gap: Genetic profiling of B-cell lymphomas using integrative whole-exome and whole-transcriptome sequencing

Anthony Ghanem, Aditya Sharma, Donald Green et al. Nov 03, 2025 pp. 7067-7067 10.1182/blood-2025-7067

Abstract Background: The treatment of B cell lymphomas has evolved significantly; however, a portion of patients still experience inferior o...

A TFPI missense variant provides protection against severe febrile neutropenia in pediatric Acute Myeloid Leukemia

Satyavardhan Rao Nittu, Richard Marrero, Xueyuan Cao et al. Nov 03, 2025 pp. 7028-7028 10.1182/blood-2025-7028

Abstract Background: Toxicity due to antileukemic agents is common in acute myeloid leukemia (AML) patients and significantly impacts morbid...

Bone marrow endothelial progenitor cells drive TKI resistance in CML via SEMA4D-plexin B1-mediated metabolic reprogramming

Shunjie Yu, Mei Bao, Xiaoshuai Zhang et al. Nov 03, 2025 pp. 355-355 10.1182/blood-2025-355

Abstract Introduction Resistance to tyrosine kinase inhibitors (TKIs) remains a major therapeutic challenge in chronic myeloid leukemia (CML...

Systemic mastocytosis with concurrent plasma cell myeloma: A rare a literature-based review of clinical, molecular, and pathologic features

Dina Soliman, Fadel Alqatati, Imran Nazir et al. Nov 03, 2025 pp. 7522-7522 10.1182/blood-2025-7522

Abstract Background: Systemic mastocytosis (SM) is a rare clonal mast cell disorder that may co-occur with other hematologic neoplasms (SM-A...

Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab-based therapies

Foteini Theodorakakou, Zoey Kapsimali, Alexandra Papadimou et al. Nov 03, 2025 pp. 2192-2192 10.1182/blood-2025-2192

Abstract Cardiac involvement remains the key prognostic factor in AL amyloidosis, but myocardium is part of an extensive vascular system cov...

Inotuzumab ozogamicin as salvage therapy for refractory/relapsed B-cell acute lymphoblastic leukemia following the failure of chimeric antigen receptor T cell therapy and allogeneic hematopoietic stem cell transplantation

Honghu Li, Luxin Yang, Lizhen Liu et al. Nov 03, 2025 pp. 7810-7810 10.1182/blood-2025-7810

Abstract Although inotuzumab ozogamicin (InO) has been approved as an effective agent for patients with refractory/relapsed (r/r) B-cell acu...

Pediatric-inspired USC ALL regimen vs hyper-CVAD in adults with ph-negative ALL: Real-world outcomes including blinatumomab in a predominantly hispanic cohort.

Karam Ashouri, Anush Ginosyan, Sophie Grove et al. Nov 03, 2025 pp. 5132-5132 10.1182/blood-2025-5132

Abstract Introduction: Pediatric-inspired regimens have improved outcomes in adolescents and young adults with acute lym...

Direct comparison of crovalimab versus eculizumab in paroxysmal nocturnalhemoglobinuria: A systematic review and meta-analysis of randomized controlled trials

Ahmed Raza, Muhammad Rafay Paracha, Anas nasir et al. Nov 03, 2025 pp. 6436-6436 10.1182/blood-2025-6436

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, clonal hematopoietic stem cell disorder characterized by complem...

Contact modality and contact intensity over time among community health workers in adult sickle cell disease

Andrea Burton, Daniel Sop, Shirley Johnson et al. Nov 03, 2025 pp. 4367-4367 10.1182/blood-2025-4367

Abstract Background The effectiveness and efficiency of medical center-based Community Health Workers, also known as Patient Navigators (PNs...

Impact of additional genetic variants in the course of erdheim-chester disease and their evolution on treatment: A multicentric longitudinal Study of 445 french patients

Félicien Triboulet, Matthias Papo, Fleur Cohen-Aubart et al. Nov 03, 2025 pp. 4770-4770 10.1182/blood-2025-4770

Abstract Introduction. Erdheim-Chester disease (ECD) is a histiocytic disorder with activating MAPK (mitogen-activated protein kinases) sign...

Underreporting of prognostic factors in real-world studies for bispecifics in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Marin Xavier, Eva Baginska, Monika Jun et al. Nov 03, 2025 pp. 4481-4481 10.1182/blood-2025-4481

Abstract BACKGROUND: Real-world patients receiving a bispecific therapy (epcoritamab or glofitamab) for third-line plus (3L+) treatment for...

Epcoritamab (epcor) monotherapy offers long-term disease control in large B-cell lymphoma (LBCL): NHL-1 subgroup analysis in patients with prior chimeric antigen receptor T-cell (CAR T) therapy from the 3-year follow-up

Catherine Thieblemont, Wojciech Jurczak, Tae Min Kim et al. Nov 03, 2025 pp. 1960-1960 10.1182/blood-2025-1960

Abstract INTRODUCTION: CAR T is approved in the relapsed/refractory (R/R) LBCL. Patients (pts) with R/R LBCL who progressed after CAR T ther...

Sepsis induces platelet‑activating anti‑PF4 antibodies with potential protective role against secondary bacterial infection

Tao Liu, Daniel Villalobos, Shiqi Cai et al. Nov 03, 2025 pp. 4875-4875 10.1182/blood-2025-4875

Abstract Background: Increasing evidence indicates the presence of anti–platelet factor 4 (PF4)/heparin antibodies in some patients with sep...

Pre-infusion ADAMTS13 and VWF levels are associated with clinical outcomes of patients receiving CAR-T cell therapy

Abdalla Shoaib, Sarah Gralnek, Forat Lutfi et al. Nov 03, 2025 pp. 2339-2339 10.1182/blood-2025-2339

Abstract Background: Chimeric antigen receptor T (CAR-T) cell therapy has been a breakthrough in the management of relapsed/refractory B cel...

CRISPR-tica.ai: A function-informed generative modeling pipeline for prioritizing drug discovery in AML

Dhvani Vora, Anthony Chan, Sheela Pangeni Pokharel et al. Nov 03, 2025 pp. 277-277 10.1182/blood-2025-277

Abstract A systematic approach to identifying novel therapeutic strategies is essential for expanding curative options in hematopoietic mali...

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial - impact of prior therapy and expanded safety analysis

Pier Luigi Zinzani, Neha Mehta-Shah, Jasmine Zain et al. Nov 03, 2025 pp. 3634-3634 10.1182/blood-2025-3634

Abstract Introduction Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of aggressive lymphomas that have a p...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page